BRIEF-Amgen says erenumab significantly reduces monthly migraine days in patients with episodic migraine in first phase 3 study
September 28, 2016 at 16:43 PM EDT
* Amgen announces erenumab significantly reduces monthly migraine days in patients with episodic migraine in first phase 3 study